CytomX Therapeutics

CytomX reported an expanded collaboration with Regeneron and received an upfront payment of $37 million for the selection of target molecules for two additional programs; the stock rose about 4.3% in premarket trading. The partnership combines CytomX's PROBODY platform with Regeneron’s Veloci-Bi platform to develop conditionally activated bispecific antibodies against cancer. Regeneron secured the option for up to six additional target molecules; potential total payouts including milestones and commercial payments could amount to around $4 billion, and tiered worldwide royalties are also provided for. » Plus sur de.investing.com

CytomX reported Q1 2026 EPS of -$0.10 (expectation -$0.12) and revenue of $10.3m (expectation $4.64m). Despite the positive surprises, the stock fell 3.63% in after-hours trading and showed further pressure in pre-market trading. The company holds $346.7m in cash, with a cash runway indicated through at least Q2 2028, while Varseta-M is cited as a growth driver following promising clinical results. Revenue fell year-over-year due to completed collaborations; management emphasizes expanding indications for Varseta-M and maintaining financial discipline. » Plus sur de.investing.com

CytomX presented phase‑1 data on Varsetatug Masetecan (Varseta‑M) in heavily pretreated patients with metastatic colorectal cancer, reporting confirmed overall response rates of 32% (10 mg/kg) and 20% (8.6 mg/kg) and disease control rates of 84–90%. Median progression‑free survival was 7.1 months (10 mg/kg) versus historical controls of 2.0–3.7 months, and the durability of responses was described as compelling. Prophylactic measures and AIBW dosing markedly reduced the rate of severe diarrhea in optimized cohorts; severe treatment‑related adverse events occurred in 25%. Cash of $347 million (cash runway to H2 2028) and planned dose‑optimization data, FDA engagements and combination studies are near‑term milestones. » Plus sur de.investing.com